TTP: Phase II study of danazol with plasma exchange and steroids for the treatment of thrombotic thrombocytopenic purpura
||Mala Varma, MD
| Time frame of study:
|Location of Study:
Beth Israel Medical Center
St.Luke's-Roosevelt Hospital Center
Continuum Cancer Research Program
The standard of care for Thrombotic Thrombocytopenic Purpura (TTP or Moschcowitz syndrome) is plasma exchange (removal and replacement of components of the blood). TTP is a rare disorder of the blood where blood clots form in blood vessels throughout the body. The purpose of this clinical study is to find out if the administration of Danazol (a hormonal drug) with plasma exchange and corticosteroids (Prednisone) will reduce the number of plasma exchanges needed to control TTP and if this treatment is better than administering only plasma exchange with corticosteroids.
- Subject must be between 18 and 60 years of age.
- New onset or previously diagnosed TTP.
- PT and PTT normal (Tests used to determine anti-blood clotting function).
- Subject is not pregnant or breastfeeding.
- Subject is not positive for HIV, Hepatits B, and Hepatitis C.
Please call for more information